Patients infected with HIV type 1 subtype CRF01-AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine

AIDS Research and Human Retroviruses

Volumn 26, Issue 6, 2010, Pages 609-611

  Manosuthi, Weerawat ^a,b   Butler, David M ^c   Chantratita, Wasun ^b   Sukasem, Chonlaphat ^b   Richman, Douglas D ^c,d   Smith, Davey M ^c,d  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; PYRIDAZINE DERIVATIVE;

CLINICAL PRACTICE; CODON; CROSS RESISTANCE; DEMOGRAPHY; DRUG EFFICACY; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOUTHEAST ASIA; THAILAND; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL GENETICS; VIRUS GENE; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN; WORLD HEALTH ORGANIZATION; ANTIVIRAL RESISTANCE; DRUG EFFECTS; HIV INFECTIONS; VIROLOGY;

ANTI-HIV AGENTS; BENZOXAZINES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; NEVIRAPINE; PYRIDAZINES; TREATMENT FAILURE;

EID: 77954203618     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0107     Document Type: Letter

References (18)

1. Hammer SM, Eron JJ Jr, Reiss P, et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300(5): 555-570.
2. Vingerhoets J, Azijn H, Fransen E, et al.: TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol 2005; 79(20):12773-12782.
3. Lazzarin A, Campbell T, Clotet B, et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a rando-mised, double-blind, placebo-controlled trial. Lancet 2007; 370(9581):39-48.
4. Madruga JV, Cahn P, Grinsztejn B, et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370(9581):29-38.
5. Vingerhoets J, Peeters M, Azijn H, et al.: An update on the list of NNRTI mutations associated with decreased virological response to etravirine: Multivariate analysis on the pooled DUET-1 and DUET-2 clinical trial data. Antivir Ther 2008;13(Suppl 3):A26
6. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006;20(16):W13-W23.
7. Llibre JM, Santos JR, Puig T, et al.: Prevalence of etravirineassociated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother 2008; 62(5):909-913.
8. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, and Chantratita W: Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting. Curr HIV Res 2008; 6(5):474-476.
9. Hirsch MS, Gunthard HF, Schapiro JM, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008;47(2):266-285.
10. Martinez-Cajas JL, Pant-Pai N, Klein MB, and Wainberg MA: Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: A systematic review of virologic and biochemical evidence. AIDS Rev 2008;10(4): 212-223.
11. Kosakovsky Pond SL and Smith DM: Are all subtypes created equal? The effectiveness of antiretroviral therapy against non-subtype B HIV-1. Clin Infect Dis 2009;48(9): 1306-1309.
12. Sungkanuparph S, Anekthananon T, Hiransuthikul N, et al.: Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: The recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai 2008;91(12): 1925-1935.
13. Richman DD, Havlir D, Corbeil J, et al.: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68(3):1660-1666.
14. Bacheler LT, Anton ED, Kudish P, et al.: Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000;44(9):2475-2484.
15. Lapadula G, Calabresi A, Castelnuovo F, et al.: Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. Antivir Ther 2008;13(4):601-605.
16. Scaling upAntiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach. Geneva: Joint United Nations Programme on HIV=AIDS (UNAIDS) and World Health Organization (WHO), 2006 revision.
17. Booth CL and Geretti AM: Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 2007;59(6):1047-1056.
18. Smith DM, Wong JK, Shao H, et al.: Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: Implications for secondary transmission. J Infect Dis 2007;196(3):356-360.